MONTREAL – (COMMERCIAL THREAD) – On December 9, 2021, Medisca entered into an exclusive global manufacturing, supply, licensing and distribution agreement with Padagis (formerly the Rx division of Perrigo) for their ORA product line composed of the following Padagis products in finished form: ORA-Plus®, ORA-Sweet®, ORA-Sweet® SF, ORA-Blend® and ORA-Blend® SF. With this, Medisca has exclusive distribution rights in all world markets with the exception of the United States and Israel, and non-exclusive distribution rights with contractual advantages in Australia.
“This exclusive agreement reinforces Medisca’s commitment as a pioneer in personalized medicine around the world,” said Panagiota Danopoulos, senior vice president of global strategy and innovation, Medisca. “The partnership with Padagis is another important step in expanding our reach, as we continue to make the power of the Medisca brands a global pioneer in the areas of pharmaceutical preparation, scientific laboratories, cosmetics and other health care. ”
Developed over 20 years ago by Paddock Laboratories, which was acquired by Perrigo in 2011, ORA products are manufactured by Padagis in Minnesota and are the oldest oral preparation vehicles on the market, with over 150 studies stability to support their use. In fact, this unrivaled portfolio of studies is the key to why many view ORA products as the oral vehicles of choice across the world. Outside of prep, the ORA brand continues to make its mark, which can be found in department stores and over-the-counter products and included in finished drugs approved by the FDA.
“So far, the ORA product line has used multiple distributors around the world,” says Colter VanStedum, Executive Vice President and Chief Growth Officer of Padagis. “Our decision to centralize distribution through Medisca was strongly influenced by their global distribution capabilities. ORA products have vast potential in critical patient care – particularly pediatric care – and are expected to be widely available to pharmacists, physicians and, most importantly, patients – in all markets around the world. The creation of this partnership was a strategic decision to maximize the positive impact on patients around the world. ”
Danopoulos adds: “Medisca’s quality standard and its international network are what makes it possible to sign such an agreement. This is another key step in our commitment to growth and leadership, making a significant and lasting difference in emerging markets. ”
With this agreement, Medisca will also file international trademark applications in certain countries on its behalf.
MEDISCA is a global healthcare leader with a well-established foundation in pharmaceutical preparation and advancements in scientific laboratories, cosmetics and other healthcare industries. For more than 30 years, MEDISCA has served pharmacies and paramedical health establishments with cutting-edge offers and a passionate commitment, developing a global network dedicated to personalized medicine. Through genuine relationships, worry-free experiences, practical processes and strategic global partnerships, MEDISCA provides innovative and superior products, cutting-edge services and world-class support systems. For more information on MEDISCA, please visit www.medisca.com, and follow us on Twitter at @medica.
PADAGIS is dedicated to improving the well-being of as many patients and consumers as possible by developing, manufacturing and distributing high quality and affordable specialty health products. The company is a leading supplier of comprehensive topical pharmaceuticals and other specialty pharmaceuticals, employing more than 1,300 people worldwide. Visit PADAGIS online at (http://www.padagis.com).